UroGen Pharma (NASDAQ:URGN) Upgraded at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma (NASDAQ:URGN) to a strong-buy rating in a report published on Monday morning, Zacks.com reports.

Other analysts have also recently issued reports about the stock. Guggenheim initiated coverage on shares of UroGen Pharma in a report on Thursday, August 22nd. They set a “buy” rating and a $40.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research note on Thursday, October 3rd. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $48.38.

UroGen Pharma Stock Up 1.9 %

Shares of UroGen Pharma stock opened at $12.84 on Monday. The business has a 50-day moving average price of $13.48 and a 200 day moving average price of $14.36. UroGen Pharma has a fifty-two week low of $10.60 and a fifty-two week high of $20.70. The firm has a market cap of $301.15 million, a P/E ratio of -3.78 and a beta of 1.11. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The firm had revenue of $21.85 million during the quarter, compared to analyst estimates of $23.69 million. On average, sell-side analysts forecast that UroGen Pharma will post -3.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Great Point Partners LLC grew its position in shares of UroGen Pharma by 10.9% during the second quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock worth $48,767,000 after acquiring an additional 285,714 shares during the last quarter. Point72 Asset Management L.P. grew its position in UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after purchasing an additional 1,337,257 shares during the last quarter. Cowen AND Company LLC increased its stake in shares of UroGen Pharma by 29.1% in the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock valued at $35,229,000 after purchasing an additional 472,893 shares during the period. Millennium Management LLC raised its holdings in shares of UroGen Pharma by 2,672.0% during the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after buying an additional 1,119,019 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of UroGen Pharma during the first quarter worth approximately $4,008,000. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.